Sanofi India is currently trading at Rs. 4537.40, up by 81.55 points or 1.83% from its previous closing of Rs. 4455.85 on the BSE.
The scrip opened at Rs. 4470.00 and has touched a high and low of Rs. 4550.00 and Rs. 4461.95 respectively. So far 59 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4651.10 on 13-Nov-2015 and a 52 week low of Rs. 3090.00 on 27-Apr-2015.
Last one week high and low of the scrip stood at Rs. 4618.00 and Rs. 4425.00 respectively. The current market cap of the company is Rs. 10358.83 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 29.32% and 10.28% respectively.
Sanofi India has completed the sale of its commercial property, being land admeasuring 5493.1 square meters bearing Survey No. 54-A Hissa No. 2 and C.T.S. No. 18 of Village Chakala, Andheri (East), Mumbai along with the building known as ‘Aventis House’ on November 20, 2015, upon fulfillment of the conditions.
The company has received the entire sale consideration of Rs111.00 crore from the purchaser. The board of directors earlier at their meeting held on July 21, 2015 had approved for the same.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: